LEMD is found to promote proliferation in gastric cancer via activating the PI3K/Akt signaling pathway (56), and is also found to be active in tumorigenesis in colorectal cancer (57) and prostate cancer (58). This evidence concerns the gene AKT1 and prostate carcinoma.